Literature DB >> 32020086

Resistance looms for KRASG12C inhibitors.

Aaron N Hata1, Alice T Shaw2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32020086     DOI： 10.1038/s41591-020-0765-z

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  17 in total

1.  Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.

Authors:  Timothy F Burns; Hossein Borghaei; Suresh S Ramalingam; Tony S Mok; Solange Peters
Journal:  J Clin Oncol       Date:  2020-10-26       Impact factor: 44.544

2.  Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells.

Authors:  Jang Hee Han; Yong Keon Kim; Hakhyun Kim; Jooyoung Lee; Myung Joon Oh; Sang Bum Kim; Minjee Kim; Kook Hwan Kim; Hyun Ju Yoon; Myung-Shik Lee; John D Minna; Michael A White; Hyun Seok Kim
Journal:  Cancer Commun (Lond)       Date:  2022-07-15

Review 3.  Precision Therapy of Pancreatic Cancer: From Bench to Bedside.

Authors:  Katrin Jana Ciecielski; Alexandra Berninger; Hana Algül
Journal:  Visc Med       Date:  2020-10-06

4.  SP3-FAIMS Chemoproteomics for High-Coverage Profiling of the Human Cysteinome*.

Authors:  Tianyang Yan; Heta S Desai; Lisa M Boatner; Stephanie L Yen; Jian Cao; Maria F Palafox; Yasaman Jami-Alahmadi; Keriann M Backus
Journal:  Chembiochem       Date:  2021-02-18       Impact factor: 3.164

Review 5.  Glycogen Synthase Kinase 3β in Cancer Biology and Treatment.

Authors:  Takahiro Domoto; Masahiro Uehara; Dilireba Bolidong; Toshinari Minamoto
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

Review 6.  Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.

Authors:  Kinga Nyíri; Gergely Koppány; Beáta G Vértessy
Journal:  Cancer Metastasis Rev       Date:  2020-12       Impact factor: 9.264

Review 7.  Mechanisms of Resistance to KRASG12C Inhibitors.

Authors:  Victoria Dunnett-Kane; Pantelis Nicola; Fiona Blackhall; Colin Lindsay
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

8.  The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.

Authors:  G Saturno; F Lopes; I Niculescu-Duvaz; D Niculescu-Duvaz; A Zambon; L Davies; L Johnson; N Preece; R Lee; A Viros; D Holovanchuk; M Pedersen; R McLeary; P Lorigan; N Dhomen; C Fisher; U Banerji; E Dean; M G Krebs; M Gore; J Larkin; R Marais; C Springer
Journal:  Ann Oncol       Date:  2020-10-29       Impact factor: 32.976

Review 9.  The Metabolic Landscape of RAS-Driven Cancers from biology to therapy.

Authors:  Suman Mukhopadhyay; Matthew G Vander Heiden; Frank McCormick
Journal:  Nat Cancer       Date:  2021-03-24

10.  Overcoming Resistance to Drugs Targeting KRASG12C Mutation.

Authors:  Delong Jiao; Shengyu Yang
Journal:  Innovation (Camb)       Date:  2020-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.